<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML><HEAD>
<META content="text/html; charset=iso-8859-1" http-equiv=Content-Type>
<META name=GENERATOR content="MSHTML 8.00.6001.19154">
<STYLE></STYLE>
</HEAD>
<BODY bgColor=#ffffff>
<BLOCKQUOTE
style="BORDER-LEFT: #000000 2px solid; PADDING-LEFT: 5px; PADDING-RIGHT: 0px; MARGIN-LEFT: 5px; MARGIN-RIGHT: 0px">
<DIV style="FONT: 10pt arial">
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN
style="FONT-FAMILY: Arial; FONT-SIZE: 10pt" lang=CA>Dear all, </SPAN><SPAN
style="FONT-SIZE: 10pt" lang=CA><?xml:namespace prefix = o ns =
"urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-SIZE: 10pt"
lang=CA><FONT face="Times New Roman"> <o:p></o:p></FONT></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN class=hps><SPAN
style="FONT-FAMILY: Arial; COLOR: #333333; FONT-SIZE: 10pt; mso-ansi-language: EN"
lang=EN>Within the context</SPAN></SPAN><SPAN
style="FONT-FAMILY: Arial; COLOR: #333333; FONT-SIZE: 10pt; mso-ansi-language: EN"
lang=EN> <SPAN class=hps><SPAN closure_uid_vztlgp="2553" Tc="null">of the
discussion</SPAN></SPAN> <SPAN closure_uid_vztlgp="2554" Tc="null"><SPAN
class=hps>that has been established</SPAN></SPAN> <SPAN
closure_uid_vztlgp="2555" Tc="null"><SPAN class=hps>regarding</SPAN></SPAN>
<SPAN closure_uid_vztlgp="2556" Tc="null"><SPAN class=hps>the transmission
of</SPAN></SPAN> <SPAN closure_uid_vztlgp="2557" Tc="null"><SPAN
class=hps>leishmaniasis</SPAN></SPAN> <SPAN closure_uid_vztlgp="2558"
Tc="null"><SPAN class=hps>without the presence of</SPAN></SPAN> <SPAN
closure_uid_vztlgp="2559" Tc="null"><SPAN class=hps>sandflies,</SPAN></SPAN>
<SPAN closure_uid_vztlgp="2560" Tc="null"><SPAN class=hps>the possibility
of</SPAN></SPAN> <SPAN closure_uid_vztlgp="2561" Tc="null">sexual <SPAN
class=hps>transmission</SPAN></SPAN> <SPAN closure_uid_vztlgp="2562"
Tc="null"><SPAN class=hps>is supported by</SPAN></SPAN> <SPAN
closure_uid_vztlgp="2564" Tc="null">our observation performed during the
course of an experimental<SPAN style="mso-spacerun: yes">
</SPAN>model<SPAN style="mso-spacerun: yes"> </SPAN>for canine
leishmaniasis when viable parasites were isolated from semen
from one infected dog. <o:p></o:p></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN
style="FONT-FAMILY: Arial; COLOR: #333333; FONT-SIZE: 10pt; mso-ansi-language: EN"
lang=EN>Ref. <SPAN style="mso-spacerun: yes"> </SPAN>Riera C and
Valladares JE. <I style="mso-bidi-font-style: normal">Parasitology Today</I>,
vol 12 nº 10, 1996)</SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN
style="FONT-FAMILY: Arial; COLOR: #333333; FONT-SIZE: 10pt; mso-ansi-language: EN"
lang=EN></SPAN> </P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN
style="FONT-FAMILY: Arial; COLOR: #333333; FONT-SIZE: 10pt; mso-ansi-language: EN"
lang=EN></SPAN><o:p></o:p></SPAN> </P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN
style="FONT-FAMILY: Arial; COLOR: #333333; FONT-SIZE: 10pt; mso-ansi-language: EN"
lang=EN><o:p><FONT color=#000000>Regards for all</FONT><BR></o:p></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN
style="FONT-FAMILY: Arial; COLOR: #333333; FONT-SIZE: 10pt; mso-ansi-language: EN"
lang=EN><o:p> </o:p></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN
style="FONT-FAMILY: Arial; COLOR: #333333; FONT-SIZE: 10pt; mso-ansi-language: EN"
lang=EN><o:p> </o:p></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN
style="FONT-FAMILY: Arial; COLOR: black; FONT-SIZE: 10pt" lang=CA>Dra.
Cristina Riera</SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN
style="FONT-FAMILY: Arial; COLOR: black; FONT-SIZE: 10pt" lang=CA>Laboratori
de Parasitologia</SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN
style="FONT-FAMILY: Arial; COLOR: black; FONT-SIZE: 10pt" lang=CA>Facultat de
Farmàcia</SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN
style="FONT-FAMILY: Arial; COLOR: black; FONT-SIZE: 10pt" lang=CA>Universitat
de Barcelona</SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN
style="FONT-FAMILY: Arial; COLOR: black; FONT-SIZE: 10pt" lang=CA>Avda Joan
XXIII/sn</SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN
style="FONT-FAMILY: Arial; COLOR: black; FONT-SIZE: 10pt" lang=CA>Barcelona
08028</SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN
style="FONT-FAMILY: Arial; COLOR: black; FONT-SIZE: 10pt" lang=CA>Tel 93 402
45 02</SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN
style="FONT-FAMILY: Arial; COLOR: black; FONT-SIZE: 10pt" lang=CA>Fax 93 402
45 04</SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN
style="FONT-FAMILY: Arial; COLOR: black; FONT-SIZE: 10pt" lang=CA><A
href="mailto:mcriera@ub.edu">mcriera@ub.edu</A></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN
style="FONT-FAMILY: Arial; COLOR: #333333; FONT-SIZE: 10pt; mso-ansi-language: ES"><o:p> </o:p></SPAN></P></DIV>
<DIV style="FONT: 10pt arial"> </DIV>
<DIV style="FONT: 10pt arial"> </DIV>
<DIV style="FONT: 10pt arial"> </DIV>
<DIV style="FONT: 10pt arial"> </DIV>
<DIV style="FONT: 10pt arial"> </DIV>
<DIV style="FONT: 10pt arial"> </DIV>
<DIV style="FONT: 10pt arial"> </DIV>
<DIV style="FONT: 10pt arial"> </DIV>
<DIV style="FONT: 10pt arial"> </DIV>
<DIV style="FONT: 10pt arial">----- Original Message ----- </DIV>
<DIV
style="FONT: 10pt arial; BACKGROUND: #e4e4e4; font-color: black"><B>From:</B>
<A title=chncosta@gmail.com href="mailto:chncosta@gmail.com">Carlos Costa</A>
</DIV>
<DIV style="FONT: 10pt arial"><B>To:</B> <A
title=KwangPoo.Chang@rosalindfranklin.edu
href="mailto:KwangPoo.Chang@rosalindfranklin.edu">Chang, Kwang-Poo</A> </DIV>
<DIV style="FONT: 10pt arial"><B>Cc:</B> <A title=leish-l@lineu.icb.usp.br
href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</A> </DIV>
<DIV style="FONT: 10pt arial"><B>Sent:</B> Saturday, October 22, 2011 3:13
PM</DIV>
<DIV style="FONT: 10pt arial"><B>Subject:</B> Re: [Leish-l] RES: testing
vaccinated dogs for immunopotentiation</DIV>
<DIV><BR></DIV>
<DIV><FONT color=#000000><FONT size=4><FONT face=verdana,sans-serif>Dear
KP,</FONT></FONT></FONT></DIV><FONT color=#000000><FONT size=4><FONT
face=verdana,sans-serif>
<DIV><FONT color=#000000><FONT size=4><FONT
face=verdana,sans-serif><BR></FONT></FONT></FONT></DIV>Leishmania can be
recovered from genital & oral mucosa or secretions from humans and
animals. Direct transmission has been documented via blood transfusion, sex
and vertical in humans and dogs. So, it exists. The question reside in is its
magnitude and importance.</FONT></FONT></FONT>
<DIV><FONT color=#000000><FONT size=4><FONT
face=verdana,sans-serif><BR></FONT></FONT></FONT></DIV>
<DIV><FONT color=#000000><FONT size=4><FONT face=verdana,sans-serif>It took me
a few days to respond to your call because I was searching my older references
looking for a particular one, actually an abstract of a meeting, showing that
if you put one infected hamster in sand fly-proof free cage, with time most
will get infected. Hopefully one of you will find it (or do it again), since I
could not find mine. </FONT></FONT></FONT></DIV>
<DIV><FONT color=#000000><FONT size=4><FONT
face=verdana,sans-serif><BR></FONT></FONT></FONT></DIV>
<DIV><FONT color=#000000><FONT size=4><FONT face=verdana,sans-serif>Months
ago, talking to Dr. Sinval Brandão-Filho, the next host of WorldLeish, we
wondered if a low prevalence rodent cycle could not feed a dog cycle and
thereafter human transmission. It sounds logic if, and only if, in fact there
is a rodent cycle (some data suggest it does not, but others (Jeff Shaw's)
that it does - any way, this a critical point). The logic is that canids feed
a lot on rodents (and on opossums), and are very vulnerable, and go back to
human dwellings. The same would be valid for a purely sylvatic cycle among
rodents/opossums and foxes).</FONT></FONT></FONT></DIV>
<DIV><FONT color=#000000><FONT size=4><FONT
face=verdana,sans-serif><BR></FONT></FONT></FONT></DIV>
<DIV><FONT color=#000000><FONT size=4><FONT face=verdana,sans-serif>Of course,
rodents may not be required if oral transmission among dogs is possible and
common, as American, Canadian and Dutch kennel data suggest. But since there
is a large overlap between the presence of sandflies and zoonotic kala-azar in
endemic countries such a transmission may have a limited role and may be
restricted to animals that are confined in groups or to stray dogs and
sylvatic canids, but not to solitary animals restricted to
households.</FONT></FONT></FONT></DIV>
<DIV><FONT color=#000000><FONT size=4><FONT
face=verdana,sans-serif><BR></FONT></FONT></FONT></DIV>
<DIV><FONT color=#000000><FONT size=4><FONT face=verdana,sans-serif>Any way,
this a largely under investigated subject, which can bring surprises to the
presently established & dominating knowledge. Deserves a lot of
funding.</FONT></FONT></FONT></DIV>
<DIV><FONT color=#000000><FONT size=4><FONT
face=verdana,sans-serif><BR></FONT></FONT></FONT></DIV>
<DIV><FONT class=Apple-style-span size=4 face="verdana, sans-serif">One last
note: if it shows to be indeed important, sandfly challenge may not be
required for vaccine evaluation. </FONT></DIV>
<DIV><FONT color=#000000><FONT size=4><FONT
face=verdana,sans-serif><BR></FONT></FONT></FONT></DIV>
<DIV><FONT color=#000000><FONT size=4><FONT
face=verdana,sans-serif>Cheers,</FONT></FONT></FONT></DIV>
<DIV><FONT color=#000000><FONT size=4><FONT
face=verdana,sans-serif><BR></FONT></FONT></FONT></DIV>
<DIV><FONT color=#000000><FONT size=4><FONT face=verdana,sans-serif>Carlos.
<BR></FONT></FONT></FONT><BR>
<DIV class=gmail_quote>2011/10/21 Chang, Kwang-Poo <SPAN dir=ltr><<A
href="mailto:KwangPoo.Chang@rosalindfranklin.edu">KwangPoo.Chang@rosalindfranklin.edu</A>></SPAN><BR>
<BLOCKQUOTE
style="BORDER-LEFT: #ccc 1px solid; MARGIN: 0px 0px 0px 0.8ex; PADDING-LEFT: 1ex"
class=gmail_quote>Carlos Costa brought my attention to this possibility as
well. Carlos may want to comment on this ? Is this a hypothesis based on
common sense or on observation/experimental data ?<BR><FONT
color=#888888><BR>KP<BR></FONT>
<DIV>
<DIV></DIV>
<DIV class=h5><BR>-----Original Message-----<BR>From: <A
href="mailto:leish-l-bounces@lineu.icb.usp.br">leish-l-bounces@lineu.icb.usp.br</A>
[mailto:<A
href="mailto:leish-l-bounces@lineu.icb.usp.br">leish-l-bounces@lineu.icb.usp.br</A>]
On Behalf Of <A
href="mailto:mauro.marzochi@ipec.fiocruz.br">mauro.marzochi@ipec.fiocruz.br</A><BR>Sent:
Wednesday, October 19, 2011 2:26 PM<BR>To: <A
href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</A><BR>Subject:
Re: [Leish-l] RES: testing vaccinated dogs for
immunopotentiation<BR><BR>Dear All,<BR>In the past, it was believed that in
the Mediterranean region the<BR>visceral leishmaniasis transmission to
children could be attributed to<BR>contamination of healthy children by the
saliva of dogs infected with<BR>Leishmania infantum (Alencar?; Hommel?).
Thus, the inter canine<BR>transmission in confined environments could
not be established by the<BR>contamination of food shared between infected
and uninfected dogs?<BR><BR>Mauro C A
Marzochi<BR>IPEC-Fiocruz/CNPq<BR><BR><BR><BR><BR><BR>On Wed, 19 Oct 2011
08:25:45 -0500, Petersen, Christine A [V PTH]<BR>wrote:<BR>> Dear
all-<BR>> Thanks for the review. Vertical infection is maintaining
infection<BR>> in dogs in the United States. We continue to look
for vector<BR>> transmission, and despite having potential sand fly
vectors, no<BR>> infected flies to date.<BR>> Christy Petersen<BR>>
-----Original Message-----<BR>> From: <A
href="mailto:leish-l-bounces@lineu.icb.usp.br">leish-l-bounces@lineu.icb.usp.br</A><BR>>
[mailto:<A
href="mailto:leish-l-bounces@lineu.icb.usp.br">leish-l-bounces@lineu.icb.usp.br</A>]
On Behalf Of Courtenay,<BR>> Orin<BR>> Sent: Wednesday, October 19,
2011 3:46 AM<BR>> To: <A
href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</A>; <A
href="mailto:jayusp@hotmail.com">jayusp@hotmail.com</A><BR>> Subject: Re:
[Leish-l] RES: testing vaccinated dogs for<BR>>
immunopotentiation<BR>><BR>> Dear all,<BR>> I attach a recent
review of evidence for non-sandfly transmission<BR>> routes and cycles in
different hosts.<BR>><BR>> It is worth distinguishing between
vaccination outcomes: one that<BR>> provides individual protection versus
one that provides community<BR>> protection (herd immunity) by
interrupting the transmission cycle<BR>> (R0<1). The attached review
concludes that vertical infection is very<BR>> unlikely to maintain
transmission independent of the dog-sandfly-dog<BR>>
cycle.<BR>><BR>> Orin<BR>><BR>><BR>> Dr. Orin
Courtenay<BR>> Reader<BR>> School of Life Sciences<BR>> University
of Warwick<BR>> Gibbet Hill Road<BR>> Coventry<BR>> CV4 7AL<BR>>
++44 +2476 524550<BR>> skype: orin.courtenay<BR>> <A
href="mailto:orin.courtenay@warwick.ac.uk">orin.courtenay@warwick.ac.uk</A><BR>>
<A href="http://www2.warwick.ac.uk/fac/sci/lifesci/people/ocourtenay/"
target=_blank>http://www2.warwick.ac.uk/fac/sci/lifesci/people/ocourtenay/</A><BR>><BR>>
Emails over 10Mb will not reach me. If you want to send large files<BR>>
use the following: <A
href="https://files.warwick.ac.uk/orincourtenay/sendto"
target=_blank>https://files.warwick.ac.uk/orincourtenay/sendto</A><BR>><BR>><BR>><BR>>
-----Original Message-----<BR>> From: <A
href="mailto:leish-l-bounces@lineu.icb.usp.br">leish-l-bounces@lineu.icb.usp.br</A><BR>>
[mailto:<A
href="mailto:leish-l-bounces@lineu.icb.usp.br">leish-l-bounces@lineu.icb.usp.br</A>]
On Behalf Of Chang,<BR>> Kwang-Poo<BR>> Sent: 17 October 2011
18:54<BR>> To: Patrick Bastien; <A
href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</A><BR>>
Subject: Re: [Leish-l] RES: testing vaccinated dogs for<BR>>
immunopotentiation<BR>><BR>> Dear Patrick,<BR>><BR>> Thanks a
lot for the article from Brazil about vertical transmission<BR>> of
canine leishmaniasis. The work is significant and was done by<BR>>
examining stillborn pups.<BR>><BR>> Christy's recent paper extended
this and the other earlier finding of<BR>> Leishmania in fetus to live
pups. Together, they constitute strong<BR>> evidence for vertical
transmission of Leishmania in dogs. As pointed<BR>> out in the article,
its potential significance in epidemiology awaits<BR>> further study.
This is also true for its implication in considering<BR>> vaccination,
etc.<BR>><BR>> KP<BR>><BR>><BR>><BR>> -----Original
Message-----<BR>> From: <A
href="mailto:leish-l-bounces@lineu.icb.usp.br">leish-l-bounces@lineu.icb.usp.br</A><BR>>
[mailto:<A
href="mailto:leish-l-bounces@lineu.icb.usp.br">leish-l-bounces@lineu.icb.usp.br</A>]
On Behalf Of Patrick<BR>> Bastien<BR>> Sent: Saturday, October 15,
2011 3:13 AM<BR>> To: <A
href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</A><BR>>
Subject: Re: [Leish-l] RES: testing vaccinated dogs for<BR>>
immunopotentiation<BR>><BR>> Dear KP,<BR>> That's it for article
[3].<BR>> (don't ask me how I got this proof, I cant' remember).<BR>>
Best wishes<BR>> P. Bastien<BR>><BR>> Professeur Patrick
Bastien<BR>> Laboratoire de Parasitologie-Mycologie, Faculté de Médecine
UMR<BR>> MIVEGEC (CNRS 5290 - IRD 224 - Université Montpellier 1)
Centre<BR>> National de Référence des Leishmania CHU de
Montpellier<BR>> 39 Avenue Charles Flahault<BR>> 34295 Montpellier
Cedex 5, France<BR>><BR>> "Chang, Kwang-Poo" <<A
href="mailto:KwangPoo.Chang@rosalindfranklin.edu">KwangPoo.Chang@rosalindfranklin.edu</A>>
a écrit :<BR>><BR>>> I also recall the description of sexual
transmission in human<BR>>> leishmaniasis in old literature, but this
is rare.<BR>>><BR>>><BR>>> Going back to the issue of
congenital transmission in human and<BR>>> canine leishmaiasis, I
listed 3 articles below from a pubmed search.<BR>>><BR>>> [1]
Pediatrics. 1999 Nov;104(5):e65.<BR>>> Congenital transmission of
visceral leishmaniasis (Kala Azar) from<BR>>> an asymptomatic mother
to her child.<BR>>> Meinecke CK, Schottelius J, Oskam L, Fleischer
B.<BR>>> SourceChildren's Hospital of Stuttgart (Olgahospital),
Stuttgart,<BR>>>
Germany.<BR>>><BR>>><BR>>><BR>>> [2] J Parasitol.
2005 Aug;91(4):970-2.<BR>>> Transplacental transmission of a North
American isolate of<BR>>> Leishmania infantum in an experimentally
infected beagle.<BR>>> Rosypal AC, Troy GC, Zajac AM, Frank G, Lindsay
DS.<BR>>> SourceDepartment of Biomedical Sciences and
Pathobiology,<BR>>> Virginia-Maryland Regional College of Veterinary
Medicine, Virginia<BR>>> Tech, Blacksburg, Virginia 24061,
USA<BR>>><BR>>> [3] Vet Parasitol. 2009 Dec 3;166(1-2):159-62.
Epub 2009 Aug 15.<BR>>> First report of vertical transmission of
Leishmania (Leishmania)<BR>>> infantum in a naturally infected bitch
from Brazil.<BR>>> da Silva SM, Ribeiro VM, Ribeiro RR, Tafuri WL,
Melo MN, Michalick<BR>>> MS.<BR>>> SourceDepartamento de
Parasitologia, Instituto de Ciências<BR>>> Biológicas, Universidade
Federal de Minas Gerais, 31270-901 Belo<BR>>> Horizonte, MG,
Brazil.<BR>>><BR>>> I hope Dr. Rosypal and the authors of
article [3] could make the pdf<BR>>> reprints of their articles
available, since they were published in<BR>>> journals, which are not
readily available.<BR>>><BR>>><BR>>><BR>>>
KP<BR>>><BR>>> -----Original Message-----<BR>>> From: <A
href="mailto:leish-l-bounces@lineu.icb.usp.br">leish-l-bounces@lineu.icb.usp.br</A><BR>>>
[mailto:<A
href="mailto:leish-l-bounces@lineu.icb.usp.br">leish-l-bounces@lineu.icb.usp.br</A>]
On Behalf Of Christopher<BR>>> Peacock<BR>>> Sent: Sunday,
October 09, 2011 10:33 PM<BR>>> To: <A
href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</A><BR>>>
Subject: Re: [Leish-l] RES: testing vaccinated dogs for<BR>>>
immunopotentiation<BR>>><BR>>> Hi,<BR>>> There is also
this rather bizarre story of a Gulf War veteran who<BR>>> returned
with leishmaniasis, this link is a Veterans association<BR>>> website
and suggest both sexual transmission and vertical<BR>>> transmission.
Not sure how reliable this information is but it does<BR>>> seem to be
contested in court. Would be interesting to know more<BR>>> details on
this case and whether it has any evidence to support the<BR>>> cases,
as far as I am aware there has only been one suggested case<BR>>> of
sexually transmitted Leishmania in humans documented many years<BR>>>
ago.<BR>>><BR>>> <A
href="http://www.vawatchdog.org/07/nf07/nfJUN07/nf062907-3.htm"
target=_blank>http://www.vawatchdog.org/07/nf07/nfJUN07/nf062907-3.htm</A><BR>>><BR>>>
<A href="http://www.leishmaniasis.us/Leish.html"
target=_blank>http://www.leishmaniasis.us/Leish.html</A><BR>>><BR>>>
Cheers<BR>>><BR>>> Chris<BR>>><BR>>> Associate
Professor Christopher Peacock<BR>>> Discipline of Microbiology
& Immunology M502<BR>>> School of Biomedical, Biomolecular
& Chemical Sciences<BR>>> The University of Western
Australia<BR>>> Nedlands WA 6009<BR>>><BR>>>
ph 00 61(0)8 9287 6172<BR>>> fax 00 61(0)8 9346
2912<BR>>><BR>>> -----Original Message-----<BR>>> From: <A
href="mailto:leish-l-bounces@lineu.icb.usp.br">leish-l-bounces@lineu.icb.usp.br</A><BR>>>
[mailto:<A
href="mailto:leish-l-bounces@lineu.icb.usp.br">leish-l-bounces@lineu.icb.usp.br</A>]
On Behalf Of Patrick<BR>>> Bastien<BR>>> Sent: Saturday, 8
October 2011 1:31 AM<BR>>> To: <A
href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</A><BR>>>
Subject: Re: [Leish-l] RES: testing vaccinated dogs for<BR>>>
immunopotentiation<BR>>><BR>>> There were several earlier
reports of this vertical transmission,<BR>>> even<BR>>> in the
US: among others, Rosypal AC, J.Parasitol. 2005, 970-972 and<BR>>>
113-115 Magno da Silva, Vet Parasitol 2009 Pangrazio, Vet
Parasitol<BR>>> 2009<BR>>><BR>>> Best regards<BR>>>
P. Bastien<BR>>><BR>>> Professeur Patrick Bastien<BR>>>
Laboratoire de Parasitologie-Mycologie, Faculté de Médecine UMR<BR>>>
MIVEGEC (CNRS 5290 - IRD 224 - Université Montpellier 1) Centre<BR>>>
National de Référence des Leishmania CHU de Montpellier<BR>>> 39
Avenue Charles Flahault<BR>>> 34295 Montpellier Cedex 5,
France<BR>>><BR>>> "Chang, Kwang-Poo" <<A
href="mailto:KwangPoo.Chang@rosalindfranklin.edu">KwangPoo.Chang@rosalindfranklin.edu</A>>
a écrit :<BR>>><BR>>>> What Jenni said indicates that
transplacental transmission of<BR>>>> canine<BR>>>>
leishmaniasis has some implication in considering dog
vaccination.<BR>>>><BR>>>><BR>>>><BR>>>>
Of further interest is the question of whether this
transplacental<BR>>>> transmission could also occur in other
reservoir animals or even in<BR>>>> human leishmaniasis ? I recall
the description of such transmission<BR>>>> in human cases in some
very early literature, but that has been<BR>>>> always considered
as unlikely or extremely rare, more as a<BR>>>>
hypothesis<BR>>>> than reality. This issue may have been addressed
in more recent<BR>>>> epidemiological studies of VL familial
clustering in<BR>>>> well-established<BR>>>> endemic sites
? Congenital transmission might escape our attention,<BR>>>> should
the outcome be largely asymptomatic
?<BR>>>><BR>>>><BR>>>><BR>>>>
KP<BR>>>><BR>>>><BR>>>><BR>>>>
________________________________<BR>>>><BR>>>> From:
Jennie Blackwell [mailto:<A
href="mailto:jmb37@cam.ac.uk">jmb37@cam.ac.uk</A>]<BR>>>> Sent:
Wednesday, October 05, 2011 6:46 PM<BR>>>> To: Chang,
Kwang-Poo<BR>>>> Cc: Petersen, Christine A [V PTH]; TECSA - Luiz
Ristow; John David;<BR>>>> <A
href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</A><BR>>>>
Subject: Re: [Leish-l] RES: testing vaccinated dogs for<BR>>>>
immunopotentiation<BR>>>><BR>>>><BR>>>><BR>>>>
I doubt it. Treatment might but if the mum was already infected
and<BR>>>> passed the parasite to the foetus I don't see how a
vaccine would<BR>>>> work to clear the parasite from the
foetus!<BR>>>><BR>>>><BR>>>><BR>>>>
Slightly different question as to whether vaccinating mums
will<BR>>>> give<BR>>>> them sufficient protection to not
pass the parasite to the pup in<BR>>>> utero should they get
infected themselves after
vaccination.<BR>>>><BR>>>><BR>>>><BR>>>>
Cheers all, Jennie<BR>>>><BR>>>> Jenefer M.
Blackwell<BR>>>><BR>>>> TICHR, CCHR,
UWA<BR>>>><BR>>>> Phone: <A
href="tel:%2B61%208%2094897910" value="+61894897910">+61 8
94897910</A><BR>>>><BR>>>> From my
iPhone<BR>>>><BR>>>><BR>>>> On 29 Sep 2011, at
00:36, "Chang, Kwang-Poo"<BR>>>> <<A
href="mailto:KwangPoo.Chang@rosalindfranklin.edu">KwangPoo.Chang@rosalindfranklin.edu</A>>
wrote:<BR>>>><BR>>>> Of interest is
the question of whether vaccination would<BR>>>>
clear<BR>>>> the infection of the pub, which has congenitally
inherited L<BR>>>> infantum
?<BR>>>><BR>>>><BR>>>><BR>>>>
KP<BR>>>><BR>>>><BR>>>><BR>>>><BR>>>>
________________________________<BR>>>><BR>>>><BR>>>>
From: Petersen, Christine A [V PTH]<BR>>>>
[mailto:<A
href="mailto:kalicat@iastate.edu">kalicat@iastate.edu</A>]<BR>>>><BR>>>>
Sent: Wednesday, September 28, 2011 11:23
AM<BR>>>> To: Chang, Kwang-Poo; TECSA - Luiz
Ristow; John David<BR>>>> Cc: <A
href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</A>;
Petersen, Christine A [V PTH]<BR>>>> Subject:
RE: [Leish-l] RES: testing vaccinated dogs for<BR>>>>
immunopotentiation<BR>>>><BR>>>><BR>>>><BR>>>>
The reference for this article is:<BR>>>>
<<A href="http://www.ncbi.nlm.nih.gov/pubmed/21532741"
target=_blank>http://www.ncbi.nlm.nih.gov/pubmed/21532741</A>><BR>>>>
<A href="http://www.ncbi.nlm.nih.gov/pubmed/21532741"
target=_blank>http://www.ncbi.nlm.nih.gov/pubmed/21532741</A><BR>>>><BR>>>>
As it was published in a PLoS journal its free access
to all.<BR>>>><BR>>>> Based on our
studies and recent ones from Brazil, I do<BR>>>>
believe<BR>>>> that to remove Leish from the canine reservoir,
transmission from<BR>>>> mom<BR>>>> to pup will need to be
addressed.<BR>>>><BR>>>> Christy
Petersen<BR>>>><BR>>>><BR>>>><BR>>>>
From: Chang, Kwang-Poo<BR>>>> [mailto:<A
href="mailto:KwangPoo.Chang@rosalindfranklin.edu">KwangPoo.Chang@rosalindfranklin.edu</A>]<BR>>>>
Sent: Wednesday, September 28, 2011 10:20
AM<BR>>>> To: TECSA - Luiz Ristow; John
David<BR>>>> Cc: <A
href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</A>;
Petersen, Christine A [V PTH]<BR>>>> Subject:
RE: [Leish-l] RES: testing vaccinated dogs for<BR>>>>
immunopotentiation<BR>>>><BR>>>><BR>>>><BR>>>>
Christine Petersen published an article about
transplacental<BR>>>> transmission of L infantum in the USA canine
leishmaniasis. I just<BR>>>> wonder about the implication of this
finding in considering<BR>>>> vaccination against the disease
transmitted this way
?<BR>>>><BR>>>><BR>>>><BR>>>>
KP<BR>>>><BR>>>><BR>>>><BR>>>><BR>>>>
________________________________<BR>>>><BR>>>><BR>>>>
From: <mailto:<A
href="mailto:leish-l-bounces@lineu.icb.usp.br">leish-l-bounces@lineu.icb.usp.br</A>><BR>>>>
<A
href="mailto:leish-l-bounces@lineu.icb.usp.br">leish-l-bounces@lineu.icb.usp.br</A><BR>>>>
[mailto:<A
href="mailto:leish-l-bounces@lineu.icb.usp.br">leish-l-bounces@lineu.icb.usp.br</A>]<BR>>>>
<mailto:%<A
href="mailto:5bmailto%3Aleish-l-bounces@lineu.icb.usp.br">5bmailto:leish-l-bounces@lineu.icb.usp.br</A>%5d>
On Behalf<BR>>>> Of<BR>>>> TECSA - Luiz
Ristow<BR>>>> Sent: Wednesday, September 28,
2011 9:08 AM<BR>>>> To: 'John
David'<BR>>>> Cc: <mailto:<A
href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</A>><BR>>>>
<A
href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</A><BR>>>>
Subject: [Leish-l] RES: testing vaccinated dogs
for<BR>>>>
immunopotentiation<BR>>>><BR>>>><BR>>>><BR>>>>
Hi
!<BR>>>><BR>>>><BR>>>><BR>>>>
There are these papers about<BR>>>><BR>>>>
These need a very critical reading to
discuss<BR>>>><BR>>>> This discussion
with all about the matter and these papers is<BR>>>> very welcome!
(at least for me!)<BR>>>><BR>>>>
Regards for all<BR>>>><BR>>>> Luiz
Ristow<BR>>>><BR>>>><BR>>>><BR>>>>
<image001.gif><BR>>>><BR>>>><BR>>>><BR>>>>
De: <mailto:<A
href="mailto:leish-l-bounces@lineu.icb.usp.br">leish-l-bounces@lineu.icb.usp.br</A>><BR>>>>
<A
href="mailto:leish-l-bounces@lineu.icb.usp.br">leish-l-bounces@lineu.icb.usp.br</A><BR>>>>
[mailto:<A
href="mailto:leish-l-bounces@lineu.icb.usp.br">leish-l-bounces@lineu.icb.usp.br</A>]<BR>>>>
<mailto:%<A
href="mailto:5bmailto%3Aleish-l-bounces@lineu.icb.usp.br">5bmailto:leish-l-bounces@lineu.icb.usp.br</A>%5d>
Em nome de<BR>>>> John David<BR>>>>
Enviada em: segunda-feira, 26 de setembro de 2011
18:44<BR>>>> Para: Dr GR
Rajasekariah<BR>>>> Cc: <mailto:<A
href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</A>><BR>>>>
<A
href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</A>;<BR>>>>
Carlos Gouvea; hubert mazure; <mailto:<A
href="mailto:smithyman@cellabs.com.au">smithyman@cellabs.com.au</A>><BR>>>>
<A
href="mailto:smithyman@cellabs.com.au">smithyman@cellabs.com.au</A><BR>>>>
Assunto: Re: [Leish-l] testing vaccinated dogs
for<BR>>>>
immunopotentiation<BR>>>><BR>>>><BR>>>><BR>>>>
I think that for any vaccine developed to protect
dogs<BR>>>> against<BR>>>> VL, but which is also meant to
prevent transmission of VL to<BR>>>> humans,<BR>>>> the
developers should show that after the vaccinated dog has
been<BR>>>> challenged with Leishmania, it does not transmit
Leishmania to sand<BR>>>> flies.<BR>>>><BR>>>>
John R David, M.D.<BR>>>><BR>>>>
Richard Pearson Strong Professor
Emeritus<BR>>>><BR>>>> Department of
Immunology and Infectious Diseases<BR>>>><BR>>>>
Harvard School of Public
Health<BR>>>><BR>>>> Professor of
Medicine, Harvard Medical School<BR>>>><BR>>>>
300 W. 23rd Street, Apt. 13K<BR>>>><BR>>>>
New York, NY, 10011<BR>>>><BR>>>>
Tel: <A href="tel:212%20414%208646"
value="+12124148646">212 414 8646</A><BR>>>><BR>>>>
Email: <mailto:<A
href="mailto:jdavid@hsph.harvard.edu">jdavid@hsph.harvard.edu</A>><BR>>>>
<A
href="mailto:jdavid@hsph.harvard.edu">jdavid@hsph.harvard.edu</A><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>>
On Sep 19, 2011, at 12:04 AM, Dr GR Rajasekariah
wrote:<BR>>>><BR>>>><BR>>>><BR>>>>
Hello EveryOne,<BR>>>> I
am responding to the topic on European VL Dog vaccine.<BR>>>>
It is a great challenge in devising a protective
vaccine<BR>>>> against visceral leishmaniasis in dogs. This point
equally applies<BR>>>> the same challenge for human
situation.<BR>>>> Because Th-2 response is so
dominant during VL infection,<BR>>>> modulating Th-2 into Th-1
response is a big challenge to<BR>>>>
immunologists.<BR>>>><BR>>>> Key
points lies in the presentation of appropriate antigen in<BR>>>>
appropriate dose to stimulate the Th-1 dependent protective
immune<BR>>>> response.<BR>>>> I
understand several vaccines are in the market and real<BR>>>>
efficacy of these vaccines will come out once introduced to
field<BR>>>> conditions.<BR>>>><BR>>>>
I just wanted to inform you that we have a suitable
antibody<BR>>>> kit for testing the immunopotentiation in dogs
following<BR>>>> vaccination<BR>>>> of
dogs.<BR>>>> Our assay is based on the
released promastigote antigens.<BR>>>> It is a
highly sensitive assay.<BR>>>> Currently we
supply reagents for determination of total IgG<BR>>>>
antibodies in serum.<BR>>>> If any particular
group is interested then we are able to<BR>>>> provide appropriate
reagent for detection of specific IgG2 and<BR>>>>
other<BR>>>> isotype specific antibody detection.<BR>>>>
Because our antibody detection ELISA is based on
the<BR>>>> exo-antigens such an ELISA would be of exceptional type
for<BR>>>> measuring<BR>>>> antibody response in
vaccinated animals.<BR>>>> Highly suitable for
diagnosing dogs responded to vaccines.<BR>>>><BR>>>>
Recently I came to know that some of commercial
kits were<BR>>>> found to be not useful for detecting
seroconversion in dogs<BR>>>> vaccinated with FML vaccine
(Leish-Immune) in Brazil.<BR>>>> Because we
use released antigens in our kit, any such<BR>>>>
problems<BR>>>> will overcome if they use Canine Leish IgG CELISA
(Manufacturer<BR>>>> Cellabs Pty Ltd Brookvale NSW Australia
email<BR>>>> <mailto:<A
href="mailto:sales@cellabs.com.au">sales@cellabs.com.au</A>> <A
href="mailto:sales@cellabs.com.au">sales@cellabs.com.au</A>).<BR>>>>
If any one is interested to know more about our
antibody<BR>>>> detection ELISA based on exo-antigens please
contact us.<BR>>>><BR>>>> This is for
your kind information.<BR>>>><BR>>>>
Dr GR Rajasekariah<BR>>>>
Sydney<BR>>>> Australia<BR>>>>
<mailto:<A
href="mailto:raj@cellabs.com.au">raj@cellabs.com.au</A>> <A
href="mailto:raj@cellabs.com.au">raj@cellabs.com.au</A><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>>
----- Original Message ----- From: <<BR>>>>
<mailto:<A
href="mailto:leish-l-request@lineu.icb.usp.br">leish-l-request@lineu.icb.usp.br</A>><BR>>>>
<A
href="mailto:leish-l-request@lineu.icb.usp.br">leish-l-request@lineu.icb.usp.br</A>><BR>>>>
To: < <mailto:<A
href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</A>><BR>>>>
<A
href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</A>><BR>>>>
Sent: Wednesday, August 10, 2011 5:18
PM<BR>>>> Subject: Leish-l Digest, Vol 44,
Issue 3<BR>>>><BR>>>> Send Leish-l
mailing list submissions to<BR>>>><BR>>>>
<mailto:<A
href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</A>><BR>>>>
<A
href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</A><BR>>>><BR>>>><BR>>>><BR>>>>
To subscribe or unsubscribe
via the World Wide Web,<BR>>>>
visit<BR>>>><BR>>>><BR>>>> <<A
href="http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l"
target=_blank>http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l</A>><BR>>>>
<A href="http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l"
target=_blank>http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l</A><BR>>>><BR>>>>
or, via email, send a
message with subject or body<BR>>>> 'help'
to<BR>>>><BR>>>>
<mailto:<A
href="mailto:leish-l-request@lineu.icb.usp.br">leish-l-request@lineu.icb.usp.br</A>><BR>>>>
<A
href="mailto:leish-l-request@lineu.icb.usp.br">leish-l-request@lineu.icb.usp.br</A><BR>>>><BR>>>><BR>>>><BR>>>>
You can reach the person
managing the list at<BR>>>><BR>>>>
<mailto:<A
href="mailto:leish-l-owner@lineu.icb.usp.br">leish-l-owner@lineu.icb.usp.br</A>><BR>>>>
<A
href="mailto:leish-l-owner@lineu.icb.usp.br">leish-l-owner@lineu.icb.usp.br</A><BR>>>><BR>>>><BR>>>><BR>>>>
When replying, please edit
your Subject line so it is<BR>>>> more
specific<BR>>>><BR>>>>
than "Re: Contents of Leish-l
digest..."<BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>>
Today's
Topics:<BR>>>><BR>>>><BR>>>><BR>>>>
1. European VL Dog
Vaccine - CaniLeish?: (jeffrey<BR>>>>
shaw)<BR>>>><BR>>>>
2. Re: FW: Leishmaniasis Pathology Network
(Moazzem<BR>>>> Hossain)<BR>>>><BR>>>>
3. Re: FW: Leishmaniasis
Pathology Network (Moazzem<BR>>>>
Hossain)<BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>>
---------------------------------------------------------------------<BR>>>>
-<BR>>>><BR>>>><BR>>>><BR>>>>
Message:
1<BR>>>><BR>>>>
Date: Tue, 9 Aug 2011 15:18:44 +0000<BR>>>><BR>>>>
From: jeffrey shaw <
<mailto:<A
href="mailto:jayusp@hotmail.com">jayusp@hotmail.com</A>><BR>>>>
<A
href="mailto:jayusp@hotmail.com">jayusp@hotmail.com</A>><BR>>>><BR>>>>
Subject: [Leish-l] European
VL Dog Vaccine -<BR>>>> CaniLeish?:<BR>>>><BR>>>>
To: Leish-L <
<mailto:<A
href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</A>><BR>>>>
<A
href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</A>><BR>>>><BR>>>>
Message-ID:
<<BR>>>> <mailto:<A
href="mailto:COL101-W1CDD4171D44B715B795E9CB200@phx.gbl">COL101-W1CDD4171D44B715B795E9CB200@phx.gbl</A>><BR>>>>
COL101-W1CDD4171D44B715B795E9CB200@phx.gbl><BR>>>><BR>>>>
Content-Type: text/plain;
charset="windows-1252"<BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>>
CaniLeish?:<BR>>>><BR>>>>
The European Commission granted a
marketing<BR>>>> authorisation valid throughout the European Union,
for CaniLeish to<BR>>>> Virbac S.A. on
14/03/2011.<BR>>>><BR>>>>
This vaccine, CaniLeish?, will initially be
launched<BR>>>> in Portugal at the end of the first half of 2011.
This will be<BR>>>> followed rapidly by launches in other countries
in the endemic<BR>>>> area:<BR>>>> Spain, France, Greece
and Italy (not in chronological order). This<BR>>>> roll-out takes
account of the geographical prevalence of the<BR>>>>
disease<BR>>>> and the time required to build vaccine production up
to full<BR>>>> capacity. The launch in Northern European countries
from where<BR>>>> there<BR>>>> is a flow of summer
visitors to the endemic area will be part of a<BR>>>> second
phase.<BR>>>><BR>>>>
The basis of this vaccine are excreted
proteins<BR>>>> plus<BR>>>> a saponin adjuvant purified
from Quil-A. Its efficacy was<BR>>>> determined<BR>>>> in
a<BR>>>> 2 year open field trial.<BR>>>><BR>>>>
The vaccine is given
to dogs as three injections,<BR>>>> three weeks apart, under the
skin. The first injection can be given<BR>>>> from six months of
age, the second injection is given three weeks<BR>>>> later and the
third three weeks from the second one. Afterward a<BR>>>> single
?booster?<BR>>>> should be given every year to maintain
protection.<BR>>>><BR>>>>
-------------- next part
--------------<BR>>>><BR>>>>
An HTML attachment was
scrubbed...<BR>>>><BR>>>>
URL: <<BR>>>><BR>>>> <<A
href="http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110809/f2404"
target=_blank>http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110809/f2404</A><BR>>>>
f5e<BR>>>> /attachment-0001.htm><BR>>>><BR>>>>
<A
href="http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110809/f2404f"
target=_blank>http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110809/f2404f</A><BR>>>>
5e/<BR>>>>
attachment-0001.htm><BR>>>><BR>>>><BR>>>><BR>>>>
------------------------------<BR>>>><BR>>>><BR>>>><BR>>>>
Message:
2<BR>>>><BR>>>>
Date: Wed, 10 Aug 2011 13:07:17 +0600<BR>>>><BR>>>>
From: Moazzem Hossain
<<BR>>>> <mailto:<A
href="mailto:directordcbd@gmail.com">directordcbd@gmail.com</A>><BR>>>>
<A
href="mailto:directordcbd@gmail.com">directordcbd@gmail.com</A>><BR>>>><BR>>>>
Subject: Re: [Leish-l] FW:
Leishmaniasis Pathology<BR>>>>
Network<BR>>>><BR>>>>
To: jeffrey shaw < <mailto:<A
href="mailto:jayusp@hotmail.com">jayusp@hotmail.com</A>><BR>>>>
<A href="mailto:jayusp@hotmail.com">jayusp@hotmail.com</A>>, "Prof. Paul
Kaye"<BR>>>><BR>>>>
< <mailto:<A
href="mailto:paul.kaye@york.ac.uk">paul.kaye@york.ac.uk</A>> <A
href="mailto:paul.kaye@york.ac.uk">paul.kaye@york.ac.uk</A>><BR>>>><BR>>>>
Cc: "Prof. Dr. Moazzem
Hossain" <<BR>>>> <mailto:<A
href="mailto:profdrmoazzemhossain@gmail.com">profdrmoazzemhossain@gmail.com</A>><BR>>>>
<A
href="mailto:profdrmoazzemhossain@gmail.com">profdrmoazzemhossain@gmail.com</A>>,<BR>>>><BR>>>>
Leish-L < <mailto:<A
href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</A>><BR>>>>
<A
href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</A>><BR>>>><BR>>>>
Message-ID:<BR>>>><BR>>>>
<<BR>>>><BR>>>> <mailto:<A
href="mailto:CAE-TCmS">CAE-TCmS</A>=i=WaT8cAeOXUJmot=KPvMQSLKar6CTfuUBK9M9tsUw@mail.gmai<BR>>>>
l.c<BR>>>> om><BR>>>> CAE-TCmS=i=WaT8cAeOXUJmot=<A
href="mailto:KPvMQSLKar6CTfuUBK9M9tsUw@mail.gmail.co">KPvMQSLKar6CTfuUBK9M9tsUw@mail.gmail.co</A><BR>>>>
om> m><BR>>>><BR>>>>
Content-Type: text/plain;
charset=windows-1252<BR>>>><BR>>>><BR>>>><BR>>>>
10 Aug
2011<BR>>>><BR>>>><BR>>>><BR>>>>
Dear Professor Paul
Kaye,<BR>>>><BR>>>><BR>>>><BR>>>>
Thank you for your email. Please
find attached our<BR>>>> supportive
letter<BR>>>><BR>>>>
of interest for Leishmaniasis Pathology
Network.<BR>>>><BR>>>>
Looking forward for your kind
response.<BR>>>><BR>>>><BR>>>><BR>>>>
Best
regards.<BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>>
--<BR>>>><BR>>>>
*Prof. Dr. Moazzem Hossain *<BR>>>><BR>>>>
Ex - Director Disease
Control<BR>>>><BR>>>>
Ministry of Health & Family
Welfare<BR>>>><BR>>>>
Government of Bangladesh<BR>>>><BR>>>>
*Mailing
address*:<BR>>>><BR>>>>
Founder Chairman and Project
Director<BR>>>><BR>>>>
Institute of Allergy & Clinical Immunology
of<BR>>>> Bangladesh<BR>>>>
(IACIB)<BR>>>><BR>>>>
Room 4 - 5 (2nd Floor), Green Super Market,
Green<BR>>>> Road<BR>>>><BR>>>>
Dhaka -1205,
Bangladesh.<BR>>>><BR>>>>
Phone:880-2-8115646 (O
)<BR>>>><BR>>>>
880-1715038551(Mobile)<BR>>>><BR>>>>
Email: <mailto:<A
href="mailto:directordcbd@gmail.com">directordcbd@gmail.com</A>><BR>>>>
<A
href="mailto:directordcbd@gmail.com">directordcbd@gmail.com</A><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>>
On 8/9/11, jeffrey shaw
< <mailto:<A
href="mailto:jayusp@hotmail.com">jayusp@hotmail.com</A>><BR>>>>
<A href="mailto:jayusp@hotmail.com">jayusp@hotmail.com</A>>
wrote:<BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>>
Date: Tue, 9 Aug 2011 11:58:52 +0100<BR>>>><BR>>>>
From:
<mailto:<A
href="mailto:paul.kaye@york.ac.uk">paul.kaye@york.ac.uk</A>><BR>>>>
<A
href="mailto:paul.kaye@york.ac.uk">paul.kaye@york.ac.uk</A><BR>>>><BR>>>><BR>>>><BR>>>>
Subject: Leishmaniasis Pathology
Network<BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>>
Dear all,<BR>>>><BR>>>>
Invitation to participate in a global<BR>>>>
pathology<BR>>>><BR>>>>
network
for<BR>>>><BR>>>>
research and
training in leishmaniasis<BR>>>>
(LeishPathNet)<BR>>>><BR>>>>
You may recall
the Dormy House meeting in<BR>>>>
2008<BR>>>><BR>>>>
and some
of<BR>>>><BR>>>>
the plans we put
forward? Over<BR>>>><BR>>>>
the past<BR>>>><BR>>>>
couple
years, I have also spoken more to<BR>>>> a<BR>>>> few of
you about one<BR>>>><BR>>>>
idea
that was<BR>>>><BR>>>>
formulated at
Dormy, namely of setting<BR>>>> up<BR>>>> a digital
pathology<BR>>>><BR>>>>
network. I
have<BR>>>><BR>>>>
also had
numerous discussions with the<BR>>>> major
equipment<BR>>>><BR>>>>
manufacturers
to see if<BR>>>><BR>>>>
any of them
would be supportive of<BR>>>> helping<BR>>>> us to develop
such an<BR>>>><BR>>>>
initiative.
There have<BR>>>><BR>>>>
been
two major<BR>>>><BR>>>>
develoments
recently. First,<BR>>>><BR>>>>
Carl Zeiss<BR>>>><BR>>>>
is
willing to work with us to set up an<BR>>>> integrated global
digital<BR>>>><BR>>>>
pathology<BR>>>><BR>>>>
network
(providing a significant<BR>>>> financial<BR>>>> and
technical<BR>>>><BR>>>>
contribution)
and<BR>>>><BR>>>>
second, the
Wellcome Trust is willing to<BR>>>> review a pre-proposal
to<BR>>>><BR>>>>
fund
the<BR>>>><BR>>>>
initiative
through their new Biomedical<BR>>>> Resources Grant
scheme<BR>>>><BR>>>>
(<BR>>>><BR>>>>
<<A
href="http://www.wellcome.ac.uk/Funding/Biomedical-science/Funding-schemes"
target=_blank>http://www.wellcome.ac.uk/Funding/Biomedical-science/Funding-schemes</A><BR>>>>
/St
rategic-awards-and-initiatives/wtdv031727.htm><BR>>>><BR>>>>
<A
href="http://www.wellcome.ac.uk/Funding/Biomedical-science/Funding-schemes/"
target=_blank>http://www.wellcome.ac.uk/Funding/Biomedical-science/Funding-schemes/</A><BR>>>>
Str<BR>>>>
ategic-awards-and-initiatives/wtdv031727.htm)<BR>>>><BR>>>>
.<BR>>>><BR>>>>
I have
attached an outline of the project<BR>>>>
that<BR>>>><BR>>>>
I had sent
to<BR>>>><BR>>>>
the Trust for their
initial views, which<BR>>>> I<BR>>>> think is
reasonably<BR>>>><BR>>>>
self-explanatory.<BR>>>><BR>>>>
They appeared very<BR>>>><BR>>>>
enthusiastic! The main<BR>>>><BR>>>>
question now is whether enough
of<BR>>>><BR>>>>
you are still
supportive? [ I will also<BR>>>> be<BR>>>> sending this
email to<BR>>>><BR>>>>
others, but
please feel free to<BR>>>> circulate<BR>>>>
]<BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>>
I think the<BR>>>><BR>>>>
project will be<BR>>>><BR>>>>
challenging, but success could have a<BR>>>> real
impact on the way we<BR>>>><BR>>>>
conduct<BR>>>><BR>>>>
business. It should serve not only as<BR>>>>
a<BR>>>> vehicle to enhance<BR>>>><BR>>>>
research in<BR>>>><BR>>>>
leishmaniasis, but the model would be<BR>>>>
equally applicable across<BR>>>><BR>>>>
a broad range<BR>>>><BR>>>>
of diseases and global challenges<BR>>>>
(with<BR>>>> leishmaniasis setting<BR>>>><BR>>>>
the pace).<BR>>>><BR>>>>
If we wish to<BR>>>><BR>>>>
proceed, the requirements<BR>>>><BR>>>>
are that we submit a pre-proposal to<BR>>>>
the<BR>>>> Trust by Oct 18th 2011.<BR>>>><BR>>>>
This pre-proposal is short (4
sections<BR>>>> of<BR>>>> 350 words)
and<BR>>>><BR>>>>
requires<BR>>>><BR>>>>
letters of support from the community.<BR>>>><BR>>>>
If you are<BR>>>><BR>>>>
supportive of the idea that<BR>>>><BR>>>>
we try to take this forward (and there<BR>>>>
is plenty of scope for<BR>>>><BR>>>>
later iteration<BR>>>><BR>>>>
of the detail), I would be grateful if<BR>>>> you could
please provide<BR>>>><BR>>>>
me with a<BR>>>><BR>>>>
letter of support by September<BR>>>><BR>>>>
12th<BR>>>><BR>>>>
2011, indicating whether you
would<BR>>>> like to be a network<BR>>>><BR>>>>
partner if the
bid<BR>>>><BR>>>>
is
successful. You could<BR>>>><BR>>>>
also be<BR>>>><BR>>>>
supportive but not wish to become<BR>>>> directly involved at
this<BR>>>><BR>>>>
stage,
and such<BR>>>><BR>>>>
letters
are equally valuable. Your<BR>>>> letter might also stress
the<BR>>>><BR>>>>
added
value<BR>>>><BR>>>>
that
the network could provide, its<BR>>>> importance for research
and<BR>>>><BR>>>>
training and/or<BR>>>><BR>>>>
for progressing the translational<BR>>>>
agenda.<BR>>>><BR>>>>
It
would also be an opportunity to<BR>>>> indicate whether
your<BR>>>><BR>>>>
group
(or<BR>>>><BR>>>>
institute, if multiple groups) would<BR>>>>
be<BR>>>> interested in bidding to<BR>>>><BR>>>>
be one of the<BR>>>><BR>>>>
initial ?designated
laboratories?.<BR>>>><BR>>>>
If there
is<BR>>>><BR>>>>
sufficient
support to<BR>>>><BR>>>>
proceed and if subsequently the<BR>>>> pre-proposal is
successful (we<BR>>>><BR>>>>
will know on 22nd<BR>>>><BR>>>>
Nov), then I will need a few<BR>>>>
volunteers<BR>>>> to help finalise
the<BR>>>><BR>>>>
full
proposal,<BR>>>><BR>>>>
which
will be due on Jan 26th 2012.<BR>>>><BR>>>>
A funding decision will be made on May<BR>>>>
26th<BR>>>><BR>>>>
2012.<BR>>>><BR>>>>
Best
wishes<BR>>>><BR>>>>
and of
course I am happy to<BR>>>><BR>>>>
discuss any points further (though I<BR>>>> will be out of
the UK from<BR>>>><BR>>>>
Aug 10 ?Sept<BR>>>><BR>>>>
12)<BR>>>><BR>>>>
Paul<BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>>
--<BR>>>><BR>>>>
Professor Paul Kaye, Ph.D.,
FRCPath.<BR>>>><BR>>>>
Deputy Dean (Research), Hull York
Medical<BR>>>> School, and<BR>>>><BR>>>>
Director, Centre for Immunology and
Infection<BR>>>><BR>>>>
Department of Biology and Hull
York Medical<BR>>>> School<BR>>>><BR>>>>
University of York<BR>>>><BR>>>>
Wentworth
Way<BR>>>><BR>>>>
York YO10
5YW<BR>>>><BR>>>>
United
Kingdom<BR>>>><BR>>>><BR>>>><BR>>>>
Tel: <A href="tel:%2B44%20%280%291904%20328840"
value="+441904328840">+44 (0)1904 328840</A><BR>>>><BR>>>>
Fax: <A href="tel:%2B44%20%280%291904%20328844"
value="+441904328844">+44 (0)1904 328844</A><BR>>>><BR>>>>
Email: <mailto:<A
href="mailto:paul.kaye@york.ac.uk">paul.kaye@york.ac.uk</A>><BR>>>>
<A href="mailto:paul.kaye@york.ac.uk">paul.kaye@york.ac.uk</A> <
<mailto:<A
href="mailto:paul.kaye@york.ac.uk">paul.kaye@york.ac.uk</A>><BR>>>>
mailto:<A
href="mailto:paul.kaye@york.ac.uk">paul.kaye@york.ac.uk</A>><BR>>>><BR>>>><BR>>>><BR>>>>
Centre Administrator and PA: Elizabeth<BR>>>>
Greensted<BR>>>><BR>>>>
Tel: 01904
328845<BR>>>><BR>>>>
Email: <mailto:<A
href="mailto:liz.greensted@york.ac.uk">liz.greensted@york.ac.uk</A>><BR>>>>
<A href="mailto:liz.greensted@york.ac.uk">liz.greensted@york.ac.uk</A> <
<mailto:<A
href="mailto:liz.greensted@york.ac.uk">liz.greensted@york.ac.uk</A>><BR>>>>
mailto:<A
href="mailto:liz.greensted@york.ac.uk">liz.greensted@york.ac.uk</A>><BR>>>><BR>>>><BR>>>><BR>>>>
Centre Email: <mailto:<A
href="mailto:cii@york.ac.uk">cii@york.ac.uk</A>><BR>>>> <A
href="mailto:cii@york.ac.uk">cii@york.ac.uk</A> < <mailto:<A
href="mailto:cii@york.ac.uk">cii@york.ac.uk</A>> mailto:<A
href="mailto:cii@york.ac.uk">cii@york.ac.uk</A>><BR>>>><BR>>>><BR>>>><BR>>>>
Centre website: <<A href="http://www.york.ac.uk/cii"
target=_blank>http://www.york.ac.uk/cii</A>><BR>>>> <A
href="http://www.york.ac.uk/cii"
target=_blank>http://www.york.ac.uk/cii</A><BR>>>><BR>>>><BR>>>><BR>>>>
Times Higher Education University of the Year<BR>>>>
2010<BR>>>><BR>>>><BR>>>><BR>>>>
Email
disclaimer:<BR>>>> <<A
href="http://www.york.ac.uk/docs/disclaimer/email.htm"
target=_blank>http://www.york.ac.uk/docs/disclaimer/email.htm</A>><BR>>>>
<A href="http://www.york.ac.uk/docs/disclaimer/email.htm"
target=_blank>http://www.york.ac.uk/docs/disclaimer/email.htm</A><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>>
------------------------------<BR>>>><BR>>>><BR>>>><BR>>>>
Message:
3<BR>>>><BR>>>>
Date: Wed, 10 Aug 2011 13:06:47 +0600<BR>>>><BR>>>>
From: Moazzem Hossain
<<BR>>>> <mailto:<A
href="mailto:directordcbd@gmail.com">directordcbd@gmail.com</A>><BR>>>>
<A
href="mailto:directordcbd@gmail.com">directordcbd@gmail.com</A>><BR>>>><BR>>>>
Subject: Re: [Leish-l] FW:
Leishmaniasis Pathology<BR>>>>
Network<BR>>>><BR>>>>
To: jeffrey shaw < <mailto:<A
href="mailto:jayusp@hotmail.com">jayusp@hotmail.com</A>><BR>>>>
<A href="mailto:jayusp@hotmail.com">jayusp@hotmail.com</A>>, "Prof. Paul
Kaye"<BR>>>><BR>>>>
< <mailto:<A
href="mailto:paul.kaye@york.ac.uk">paul.kaye@york.ac.uk</A>> <A
href="mailto:paul.kaye@york.ac.uk">paul.kaye@york.ac.uk</A>><BR>>>><BR>>>>
Cc: "Prof. Dr. Moazzem
Hossain" <<BR>>>> <mailto:<A
href="mailto:profdrmoazzemhossain@gmail.com">profdrmoazzemhossain@gmail.com</A>><BR>>>>
<A
href="mailto:profdrmoazzemhossain@gmail.com">profdrmoazzemhossain@gmail.com</A>>,<BR>>>><BR>>>>
Leish-L < <mailto:<A
href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</A>><BR>>>>
<A
href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</A>><BR>>>><BR>>>>
Message-ID:<BR>>>><BR>>>>
<<BR>>>><BR>>>> <mailto:<A
href="mailto:CAE-TCmQNUkZdNE5w%2BZ20bjLC-">CAE-TCmQNUkZdNE5w+Z20bjLC-</A>=vvV9BCP6OLOm9f6RV-BfpXvA@mail.gmai<BR>>>>
l.c<BR>>>> om><BR>>>> CAE-TCmQNUkZdNE5w+Z20bjLC-=<A
href="mailto:vvV9BCP6OLOm9f6RV-BfpXvA@mail.gmail.co">vvV9BCP6OLOm9f6RV-BfpXvA@mail.gmail.co</A><BR>>>>
om> CAE-TCmQNUkZdNE5w+m><BR>>>><BR>>>>
Content-Type: text/plain;
charset="windows-1252"<BR>>>><BR>>>><BR>>>><BR>>>>
10 Aug
2011<BR>>>><BR>>>><BR>>>><BR>>>>
Dear Professor Paul
Kaye,<BR>>>><BR>>>><BR>>>><BR>>>>
Thank you for your email. Please
find attached our<BR>>>> supportive
letter<BR>>>><BR>>>>
of interest for Leishmaniasis Pathology
Network.<BR>>>><BR>>>>
Looking forward for your kind
response.<BR>>>><BR>>>><BR>>>><BR>>>>
Best
regards.<BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>>
--<BR>>>><BR>>>>
*Prof. Dr. Moazzem Hossain *<BR>>>><BR>>>>
Ex - Director Disease
Control<BR>>>><BR>>>>
Ministry of Health & Family
Welfare<BR>>>><BR>>>>
Government of Bangladesh<BR>>>><BR>>>>
*Mailing
address*:<BR>>>><BR>>>>
Founder Chairman and Project
Director<BR>>>><BR>>>>
Institute of Allergy & Clinical Immunology
of<BR>>>> Bangladesh<BR>>>>
(IACIB)<BR>>>><BR>>>>
Room 4 - 5 (2nd Floor), Green Super Market,
Green<BR>>>> Road<BR>>>><BR>>>>
Dhaka -1205,
Bangladesh.<BR>>>><BR>>>>
Phone:880-2-8115646 (O
)<BR>>>><BR>>>>
880-1715038551(Mobile)<BR>>>><BR>>>>
Email: <mailto:<A
href="mailto:directordcbd@gmail.com">directordcbd@gmail.com</A>><BR>>>>
<A
href="mailto:directordcbd@gmail.com">directordcbd@gmail.com</A><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>>
On 8/9/11, jeffrey shaw
< <mailto:<A
href="mailto:jayusp@hotmail.com">jayusp@hotmail.com</A>><BR>>>>
<A href="mailto:jayusp@hotmail.com">jayusp@hotmail.com</A>>
wrote:<BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>>
Date: Tue, 9 Aug 2011 11:58:52 +0100<BR>>>><BR>>>>
From:
<mailto:<A
href="mailto:paul.kaye@york.ac.uk">paul.kaye@york.ac.uk</A>><BR>>>>
<A
href="mailto:paul.kaye@york.ac.uk">paul.kaye@york.ac.uk</A><BR>>>><BR>>>><BR>>>><BR>>>>
Subject: Leishmaniasis Pathology
Network<BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>>
Dear all,<BR>>>><BR>>>>
Invitation to participate in a global<BR>>>>
pathology<BR>>>><BR>>>>
network
for<BR>>>><BR>>>>
research and
training in leishmaniasis<BR>>>>
(LeishPathNet)<BR>>>><BR>>>>
You may recall
the Dormy House meeting in<BR>>>>
2008<BR>>>><BR>>>>
and some
of<BR>>>><BR>>>>
the plans we put
forward? Over<BR>>>><BR>>>>
the past<BR>>>><BR>>>>
couple
years, I have also spoken more to<BR>>>> a<BR>>>> few of
you about one<BR>>>><BR>>>>
idea
that was<BR>>>><BR>>>>
formulated at
Dormy, namely of setting<BR>>>> up<BR>>>> a digital
pathology<BR>>>><BR>>>>
network. I
have<BR>>>><BR>>>>
also had
numerous discussions with the<BR>>>> major
equipment<BR>>>><BR>>>>
manufacturers
to see if<BR>>>><BR>>>>
any of them
would be supportive of<BR>>>> helping<BR>>>> us to develop
such an<BR>>>><BR>>>>
initiative.
There have<BR>>>><BR>>>>
been
two major<BR>>>><BR>>>>
develoments
recently. First,<BR>>>><BR>>>>
Carl Zeiss<BR>>>><BR>>>>
is
willing to work with us to set up an<BR>>>> integrated global
digital<BR>>>><BR>>>>
pathology<BR>>>><BR>>>>
network
(providing a significant<BR>>>> financial<BR>>>> and
technical<BR>>>><BR>>>>
contribution)
and<BR>>>><BR>>>>
second, the
Wellcome Trust is willing to<BR>>>> review a pre-proposal
to<BR>>>><BR>>>>
fund
the<BR>>>><BR>>>>
initiative
through their new Biomedical<BR>>>> Resources Grant
scheme<BR>>>><BR>>>>
(<BR>>>><BR>>>>
<<A
href="http://www.wellcome.ac.uk/Funding/Biomedical-science/Funding-schemes"
target=_blank>http://www.wellcome.ac.uk/Funding/Biomedical-science/Funding-schemes</A><BR>>>>
/St
rategic-awards-and-initiatives/wtdv031727.htm><BR>>>><BR>>>>
<A
href="http://www.wellcome.ac.uk/Funding/Biomedical-science/Funding-schemes/"
target=_blank>http://www.wellcome.ac.uk/Funding/Biomedical-science/Funding-schemes/</A><BR>>>>
Str<BR>>>>
ategic-awards-and-initiatives/wtdv031727.htm)<BR>>>><BR>>>>
.<BR>>>><BR>>>>
I have
attached an outline of the project<BR>>>>
that<BR>>>><BR>>>>
I had sent
to<BR>>>><BR>>>>
the Trust for their
initial views, which<BR>>>> I<BR>>>> think is
reasonably<BR>>>><BR>>>>
self-explanatory.<BR>>>><BR>>>>
They appeared very<BR>>>><BR>>>>
enthusiastic! The main<BR>>>><BR>>>>
question now is whether enough
of<BR>>>><BR>>>>
you are still
supportive? [ I will also<BR>>>> be<BR>>>> sending this
email to<BR>>>><BR>>>>
others, but
please feel free to<BR>>>> circulate<BR>>>>
]<BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>>
I think the<BR>>>><BR>>>>
project will be<BR>>>><BR>>>>
challenging, but success could have a<BR>>>> real
impact on the way we<BR>>>><BR>>>>
conduct<BR>>>><BR>>>>
business. It should serve not only as<BR>>>>
a<BR>>>> vehicle to enhance<BR>>>><BR>>>>
research in<BR>>>><BR>>>>
leishmaniasis, but the model would be<BR>>>>
equally applicable across<BR>>>><BR>>>>
a broad range<BR>>>><BR>>>>
of diseases and global challenges<BR>>>>
(with<BR>>>> leishmaniasis setting<BR>>>><BR>>>>
the pace).<BR>>>><BR>>>>
If we wish to<BR>>>><BR>>>>
proceed, the requirements<BR>>>><BR>>>>
are that we submit a pre-proposal to<BR>>>>
the<BR>>>> Trust by Oct 18th 2011.<BR>>>><BR>>>>
This pre-proposal is short (4
sections<BR>>>> of<BR>>>> 350 words)
and<BR>>>><BR>>>>
requires<BR>>>><BR>>>>
letters of support from the community.<BR>>>><BR>>>>
If you are<BR>>>><BR>>>>
supportive of the idea that<BR>>>><BR>>>>
we try to take this forward (and there<BR>>>>
is plenty of scope for<BR>>>><BR>>>>
later iteration<BR>>>><BR>>>>
of the detail), I would be grateful if<BR>>>> you could
please provide<BR>>>><BR>>>>
me with a<BR>>>><BR>>>>
letter of support by September<BR>>>><BR>>>>
12th<BR>>>><BR>>>>
2011, indicating whether you
would<BR>>>> like to be a network<BR>>>><BR>>>>
partner if the
bid<BR>>>><BR>>>>
is
successful. You could<BR>>>><BR>>>>
also be<BR>>>><BR>>>>
supportive but not wish to become<BR>>>> directly involved at
this<BR>>>><BR>>>>
stage,
and such<BR>>>><BR>>>>
letters
are equally valuable. Your<BR>>>> letter might also stress
the<BR>>>><BR>>>>
added
value<BR>>>><BR>>>>
that
the network could provide, its<BR>>>> importance for research
and<BR>>>><BR>>>>
training and/or<BR>>>><BR>>>>
for progressing the translational<BR>>>>
agenda.<BR>>>><BR>>>>
It
would also be an opportunity to<BR>>>> indicate whether
your<BR>>>><BR>>>>
group
(or<BR>>>><BR>>>>
institute, if multiple groups) would<BR>>>>
be<BR>>>> interested in bidding to<BR>>>><BR>>>>
be one of the<BR>>>><BR>>>>
initial ?designated
laboratories?.<BR>>>><BR>>>>
If there
is<BR>>>><BR>>>>
sufficient
support to<BR>>>><BR>>>>
proceed and if subsequently the<BR>>>> pre-proposal is
successful (we<BR>>>><BR>>>>
will know on 22nd<BR>>>><BR>>>>
Nov), then I will need a few<BR>>>>
volunteers<BR>>>> to help finalise
the<BR>>>><BR>>>>
full
proposal,<BR>>>><BR>>>>
which
will be due on Jan 26th 2012.<BR>>>><BR>>>>
A funding decision will be made on May<BR>>>>
26th<BR>>>><BR>>>>
2012.<BR>>>><BR>>>>
Best
wishes<BR>>>><BR>>>>
and of
course I am happy to<BR>>>><BR>>>>
discuss any points further (though I<BR>>>> will be out of
the UK from<BR>>>><BR>>>>
Aug 10 ?Sept<BR>>>><BR>>>>
12)<BR>>>><BR>>>>
Paul<BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>>
--<BR>>>><BR>>>>
Professor Paul Kaye, Ph.D.,
FRCPath.<BR>>>><BR>>>>
Deputy Dean (Research), Hull York
Medical<BR>>>> School, and<BR>>>><BR>>>>
Director, Centre for Immunology and
Infection<BR>>>><BR>>>>
Department of Biology and Hull
York Medical<BR>>>> School<BR>>>><BR>>>>
University of York<BR>>>><BR>>>>
Wentworth
Way<BR>>>><BR>>>>
York YO10
5YW<BR>>>><BR>>>>
United
Kingdom<BR>>>><BR>>>><BR>>>><BR>>>>
Tel: <A href="tel:%2B44%20%280%291904%20328840"
value="+441904328840">+44 (0)1904 328840</A><BR>>>><BR>>>>
Fax: <A href="tel:%2B44%20%280%291904%20328844"
value="+441904328844">+44 (0)1904 328844</A><BR>>>><BR>>>>
Email: <mailto:<A
href="mailto:paul.kaye@york.ac.uk">paul.kaye@york.ac.uk</A>><BR>>>>
<A href="mailto:paul.kaye@york.ac.uk">paul.kaye@york.ac.uk</A> <
<mailto:<A
href="mailto:paul.kaye@york.ac.uk">paul.kaye@york.ac.uk</A>><BR>>>>
mailto:<A
href="mailto:paul.kaye@york.ac.uk">paul.kaye@york.ac.uk</A>><BR>>>><BR>>>><BR>>>><BR>>>>
Centre Administrator and PA: Elizabeth<BR>>>>
Greensted<BR>>>><BR>>>>
Tel: 01904
328845<BR>>>><BR>>>>
Email: <mailto:<A
href="mailto:liz.greensted@york.ac.uk">liz.greensted@york.ac.uk</A>><BR>>>>
<A href="mailto:liz.greensted@york.ac.uk">liz.greensted@york.ac.uk</A> <
<mailto:<A
href="mailto:liz.greensted@york.ac.uk">liz.greensted@york.ac.uk</A>><BR>>>>
mailto:<A
href="mailto:liz.greensted@york.ac.uk">liz.greensted@york.ac.uk</A>><BR>>>><BR>>>><BR>>>><BR>>>>
Centre Email: <mailto:<A
href="mailto:cii@york.ac.uk">cii@york.ac.uk</A>><BR>>>> <A
href="mailto:cii@york.ac.uk">cii@york.ac.uk</A> < <mailto:<A
href="mailto:cii@york.ac.uk">cii@york.ac.uk</A>> mailto:<A
href="mailto:cii@york.ac.uk">cii@york.ac.uk</A>><BR>>>><BR>>>><BR>>>><BR>>>>
Centre website: <<A href="http://www.york.ac.uk/cii"
target=_blank>http://www.york.ac.uk/cii</A>><BR>>>> <A
href="http://www.york.ac.uk/cii"
target=_blank>http://www.york.ac.uk/cii</A><BR>>>><BR>>>><BR>>>><BR>>>>
Times Higher Education University of the Year<BR>>>>
2010<BR>>>><BR>>>><BR>>>><BR>>>>
Email
disclaimer:<BR>>>> <<A
href="http://www.york.ac.uk/docs/disclaimer/email.htm"
target=_blank>http://www.york.ac.uk/docs/disclaimer/email.htm</A>><BR>>>>
<A href="http://www.york.ac.uk/docs/disclaimer/email.htm"
target=_blank>http://www.york.ac.uk/docs/disclaimer/email.htm</A><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>>
-------------- next part
--------------<BR>>>><BR>>>>
A non-text attachment was
scrubbed...<BR>>>><BR>>>>
Name: Letter Leish
UK.doc<BR>>>><BR>>>>
Type: application/msword<BR>>>><BR>>>>
Size: 46080
bytes<BR>>>><BR>>>>
Desc: not available<BR>>>><BR>>>>
URL:
<<BR>>>><BR>>>> <<A
href="http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110810/73f2a"
target=_blank>http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110810/73f2a</A><BR>>>>
e6a<BR>>>> /attachment.doc><BR>>>><BR>>>> <A
href="http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110810/73f2ae"
target=_blank>http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110810/73f2ae</A><BR>>>>
6a/<BR>>>>
attachment.doc><BR>>>><BR>>>><BR>>>><BR>>>>
------------------------------<BR>>>><BR>>>><BR>>>><BR>>>>
_______________________________________________<BR>>>><BR>>>>
Leish-l mailing
list<BR>>>><BR>>>>
<mailto:<A
href="mailto:Leish-l@lineu.icb.usp.br">Leish-l@lineu.icb.usp.br</A>><BR>>>>
<A
href="mailto:Leish-l@lineu.icb.usp.br">Leish-l@lineu.icb.usp.br</A><BR>>>><BR>>>><BR>>>>
<<A href="http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l"
target=_blank>http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l</A>><BR>>>>
<A href="http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l"
target=_blank>http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l</A><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>>
End of Leish-l Digest, Vol
44, Issue 3<BR>>>><BR>>>>
**************************************<BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>>
=======<BR>>>> Email
scanned by PC Tools - No viruses or spyware found.<BR>>>>
(Email Guard: 7.0.0.26, Virus/Spyware Database:
6.18330)<BR>>>> <<A
href="http://www.pctools.com/" target=_blank>http://www.pctools.com/</A>>
<A href="http://www.pctools.com/"
target=_blank>http://www.pctools.com/</A><BR>>>>
=======<BR>>>>
_______________________________________________<BR>>>>
Leish-l mailing list<BR>>>>
<mailto:<A
href="mailto:Leish-l@lineu.icb.usp.br">Leish-l@lineu.icb.usp.br</A>> <A
href="mailto:Leish-l@lineu.icb.usp.br">Leish-l@lineu.icb.usp.br</A><BR>>>>
<<A
href="http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l"
target=_blank>http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l</A>><BR>>>>
<A href="http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l"
target=_blank>http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l</A><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>><BR>>>>
_______________________________________________<BR>>>>
Leish-l mailing list<BR>>>> <A
href="mailto:Leish-l@lineu.icb.usp.br">Leish-l@lineu.icb.usp.br</A><BR>>>>
<A
href="http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l"
target=_blank>http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l</A><BR>>>><BR>>>><BR>>><BR>>><BR>>><BR>>><BR>>>
_______________________________________________<BR>>> Leish-l mailing
list<BR>>> <A
href="mailto:Leish-l@lineu.icb.usp.br">Leish-l@lineu.icb.usp.br</A><BR>>>
<A href="http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l"
target=_blank>http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l</A><BR>>><BR>>>
--<BR>>> This message has been scanned for viruses and dangerous
content by<BR>>> MailScanner, and is believed to be
clean.<BR>>><BR>>><BR>>>
######################################################################<BR>>>
############### This e-mail message has been scanned for Viruses
and<BR>>> Content and cleared by MailMarshal<BR>>><BR>>>
######################################################################<BR>>>
############### _______________________________________________<BR>>>
Leish-l mailing list<BR>>> <A
href="mailto:Leish-l@lineu.icb.usp.br">Leish-l@lineu.icb.usp.br</A><BR>>>
<A href="http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l"
target=_blank>http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l</A><BR>>><BR>>><BR>>>
_______________________________________________<BR>>> Leish-l mailing
list<BR>>> <A
href="mailto:Leish-l@lineu.icb.usp.br">Leish-l@lineu.icb.usp.br</A><BR>>>
<A href="http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l"
target=_blank>http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l</A><BR>>><BR>><BR>><BR>><BR>>
_______________________________________________<BR>> Leish-l mailing
list<BR>> <A
href="mailto:Leish-l@lineu.icb.usp.br">Leish-l@lineu.icb.usp.br</A><BR>>
<A href="http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l"
target=_blank>http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l</A><BR>>
_______________________________________________<BR>> Leish-l mailing
list<BR>> <A
href="mailto:Leish-l@lineu.icb.usp.br">Leish-l@lineu.icb.usp.br</A><BR>>
<A href="http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l"
target=_blank>http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l</A><BR><BR>_______________________________________________<BR>Leish-l
mailing list<BR><A
href="mailto:Leish-l@lineu.icb.usp.br">Leish-l@lineu.icb.usp.br</A><BR><A
href="http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l"
target=_blank>http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l</A><BR><BR>_______________________________________________<BR>Leish-l
mailing list<BR><A
href="mailto:Leish-l@lineu.icb.usp.br">Leish-l@lineu.icb.usp.br</A><BR><A
href="http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l"
target=_blank>http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l</A><BR></DIV></DIV></BLOCKQUOTE></DIV><BR><BR
clear=all>
<DIV><BR></DIV>-- <BR>
<DIV style="TEXT-ALIGN: center"><SPAN
style="FONT-FAMILY: verdana, sans-serif"><B>Carlos H. N. Costa, MD,
DSc.</B></SPAN></DIV>
<DIV style="TEXT-ALIGN: center"><SPAN
style="FONT-FAMILY: verdana, sans-serif"><B>Sociedade Brasileira de Medicina
Tropical </B></SPAN></DIV>
<DIV style="TEXT-ALIGN: center"><B><SPAN
style="FONT-FAMILY: verdana, sans-serif"></SPAN></B><SPAN
style="FONT-FAMILY: verdana, sans-serif"><B>(Brazilian Society of Tropical
Medicine)</B></SPAN></DIV>
<DIV style="TEXT-ALIGN: center"><SPAN
style="FONT-FAMILY: verdana, sans-serif"><B>President</B></SPAN></DIV>
<DIV style="TEXT-ALIGN: center"><SPAN
style="FONT-FAMILY: verdana, sans-serif"><B><BR></B></SPAN></DIV>
<DIV style="TEXT-ALIGN: center"><SPAN
style="FONT-FAMILY: verdana, sans-serif"><B>Universidade Federal do
Piauí</B></SPAN></DIV>
<DIV>
<DIV style="TEXT-ALIGN: center"><SPAN
style="FONT-FAMILY: verdana, sans-serif"><B>Instituto de Doenças Tropicais
Natan Portella</B></SPAN></DIV>
<DIV style="TEXT-ALIGN: center"><FONT face="verdana, sans-serif"><B>Rua Artur
de Vasconcelos 151-Sul</B></FONT></DIV>
<DIV>
<DIV style="TEXT-ALIGN: center"><SPAN
style="FONT-FAMILY: verdana, sans-serif"><B>64001-450
Teresina-PI</B></SPAN></DIV><FONT face="verdana, sans-serif">
<DIV style="TEXT-ALIGN: center"><B>Brazil</B></DIV><B>
<DIV style="TEXT-ALIGN: center"><SPAN
style="FONT-WEIGHT: normal"><B>Telephones: +55 86 3221-3413 (work); +55 86
8838-3303 (mobile).</B></SPAN></DIV></B>
<DIV style="TEXT-ALIGN: center"><BR></DIV><SPAN style="FONT-SIZE: x-small">
<DIV style="TEXT-ALIGN: center">Aviso: As informações contidas nesta mensagem
são CONFIDENCIAIS, protegidas pelo sigilo legal, por direitos autorais e
destinadas exclusivamente à pessoa ou organização para a qual a mensagem foi
destinada.</DIV>
<DIV style="TEXT-ALIGN: center">Warning: This message is meant only for the
intended recipient of the transmission. It is forbidden any unauthorized
use, alteration, reproduction and distribution. If you are not the correct
recipient, please notify us immediately by return e-mail and delete this
message from your system.</DIV></SPAN></FONT></DIV></DIV><BR></DIV>
<P>
<HR>
<P></P>_______________________________________________<BR>Leish-l mailing
list<BR>Leish-l@lineu.icb.usp.br<BR>http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l<BR></BLOCKQUOTE></BODY></HTML>